190792-70-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Furanol,4-aminotetrahydro-,(3R,4S)-(9CI) is used as an intermediate in the synthesis of various pharmaceutical compounds for its unique structural properties and reactivity. Its ability to form hydrogen bonds and its compatibility with other functional groups make it a valuable component in the development of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Furanol,4-aminotetrahydro-,(3R,4S)-(9CI) serves as a versatile building block for the creation of complex organic molecules. Its presence of both amino and hydroxy groups allows for a wide range of chemical reactions, facilitating the synthesis of target molecules with specific properties and functions.
Used in Research and Development:
3-Furanol,4-aminotetrahydro-,(3R,4S)-(9CI) is utilized in research and development for its potential applications in various scientific areas. Its unique stereochemistry and reactivity make it an interesting subject for studying the effects of stereoisomerism on chemical behavior and biological activity. Additionally, it can be used to explore new reaction pathways and develop innovative synthetic methods.

Upstream product

• 190792-68-8 [(3R,4S)-4-azidotetrahydrofuran-3-yl]oxytrimethylsilane 
• 183184-50-1 trans-4-azido-3-hydroxytetrahydrofuran 
• 285-69-8 3,4-epoxytetrahydrofuran 

Downstream Products

• 215940-74-2 [(S)-1-((3S,4R)-4-Hydroxy-tetrahydro-furan-3-ylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl ester 
• 5834-36-6 3-oxa-6-azabicyclo[3.1.0]hexane 
• 1421582-94-6 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide 
• 1421582-95-7 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R,4S)-4-hydroxytetrahydrofuran-3-yl]benzamide 
• 1421582-97-9 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide 
• 1430230-65-1 tert-butyl ((3S,4R)-4-hydroxytetrahydrofuran-3-yl)carbamate 

Relevant academic research and scientific papers

FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.

NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF

There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like.)

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.

Enantioselective ring-opening of aziridines

A process for the preparation of a nucleophilic addition product of an aziridine and a nucleophile, the process comprising treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst

Diastereoselective synthesis, activity and chiral stability of cyclic alkoxyketone inhibitors of cathepsin K

The diastereoselective synthesis of a novel class of cathepsin K inhibitors together with their cathepsin K affinity and stability towards aqueous buffer is reported.